the local company VaxThera sealed an alliance with the Indian biotech company Gennova for vaccine production.
The achievement was presented by the representatives of both companies, as an important step in the production and vaccine marketing throughout Latin America, in order to be prepared for a future –and eventual– pandemic.
In fact, Jorge Emilio Osorio, CEO of VaxThera -a Sura company-, during the ratification of the agreement, was very emphatic that covid-19 showed that pharmaceutical companies can work quickly in the production of doses. And starting from there, “this is an opportunity to contribute to the development of science and technology in Colombia”.
Although the stamp that was made official this week is for the production of vaccines with messenger RNA (mRNA), before reaching that Gennova will be able to market its products in the country and throughout Latin America.
–
For Sanjay Singh, CEO of Gennova, entering this market with VaxThera will allow them to reach many people and places with excellent quality products.
Said union, according to the National Government, is in line with its health policies, which seek to generate good conditions to manufacture vaccines and to have considerable independence in terms of health security.
Even from the Casa de Nariño it was stated that the union is the product of the Science, Technology and Health Business Mission that diplomats made to India last September.
–
That is why the vice president and chancellor Marta Lucía Ramírez recently pointed out that this is very good news for the country, since without a doubt it will serve “for the development of medicines, medical supplies and vaccinesnot only for Colombia, but for the entire region, taking into account the strength that India has had globally in this health sector for a long time”.
Advances in the sector
The VaxThera company is already building a plant for the production of vaccines in the Antioquia municipality of Rionegro. The first objective to which their directors aim is to comply with the filling and packaging servicesknown in English technically as fill and finish.
For its part, Sinovac also announced last May that it is working in a manufacturing center in Colombia, which together with that of the Sura company, will reach a production of 160 million vaccines per year.
– –
